Ibrunat 140mg is an oral targeted therapy used to treat various blood cancers such as CLL, SLL, and MCL. It works by blocking Bruton's tyrosine kinase (BTK), a protein essential for cancer cell survival.
Ibrunat 140mg, manufactured by Natco Pharma, contains Ibrutinib, a Bruton's Tyrosine Kinase (BTK) inhibitor. This capsule is prescribed for treating B-cell malignancies such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström's macroglobulinemia (WM). It is a first-in-class targeted therapy that significantly slows cancer progression and improves survival.
Uses:
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Mantle Cell Lymphoma (MCL)
Waldenström's Macroglobulinemia (WM)
Marginal Zone Lymphoma (MZL)
Chronic Graft versus Host Disease (cGVHD) in select cases
Storage Instructions:
Store at 20°C–25°C (68°F–77°F)
Protect from light and moisture
Keep in original container
Keep out of reach of children
How it Works (Mechanism of Action):
Ibrutinib selectively and irreversibly binds to Bruton's tyrosine kinase (BTK), an enzyme vital for B-cell receptor signaling.
Inhibition of BTK prevents survival and proliferation of malignant B-cells
Disrupts signaling needed for cancer cell migration and adhesion
Leads to cancer cell apoptosis (programmed cell death) and slows disease progression
Side Effects:
Common Side Effects:
Diarrhea
Fatigue
Nausea
Muscle pain
Bruising or bleeding
Upper respiratory tract infections
Serious Side Effects:
Atrial fibrillation or heart rhythm problems
Hypertension (high blood pressure)
Bleeding events (serious or fatal)
Infections (bacterial, viral, fungal)
Tumor lysis syndrome
Secondary cancers (rare)
Dosage (Typical Recommended Dose):
MCL: 560 mg once daily (usually 4 capsules of 140 mg)
CLL, SLL, WM: 420 mg once daily (3 capsules of 140 mg)
Doses may be modified based on tolerance and side effects
Take daily until disease progression or unacceptable toxicity
Method of Administration:
Take the capsule orally once daily with a full glass of water
Do not open, crush, or chew the capsules
Can be taken with or without food
Take at the same time every day for best results
Precautions:
Monitor for bleeding, heart rhythm changes, and infection
Not recommended during pregnancy or breastfeeding
Use effective contraception during and at least 1 month after treatment
Regular blood tests and ECGs may be required
Caution in patients with cardiac disorders or hypertension
Strong CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce effectiveness
Increased bleeding risk with anticoagulants and antiplatelets
Avoid grapefruit and Seville oranges – they can increase drug levels
Allergies:
Avoid use in patients with known hypersensitivity to Ibrutinib
Signs of allergic reactions include:
Swelling of lips or throat
Difficulty breathing
Severe skin rash
Overdose Information:
Symptoms: Severe diarrhea, vomiting, bleeding, infections
No specific antidote; treat with supportive measures
In case of overdose, seek immediate emergency care
Missed Dose Instructions:
If missed by less than 12 hours, take it as soon as remembered
If missed by more than 12 hours, skip the dose
Do not double the dose to catch up
Additional Notes:
Patients should report any unusual bruising, infections, or heart symptoms
Blood pressure and ECG monitoring is advised during treatment
Avoid live vaccines while on treatment
Must be used only under medical supervision
Product Intro:
Ibrunat 140mg, manufactured by Natco Pharma, contains Ibrutinib, a Bruton's Tyrosine Kinase (BTK) inhibitor. This capsule is prescribed for treating B-cell malignancies such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström's macroglobulinemia (WM). It is a first-in-class targeted therapy that significantly slows cancer progression and improves survival.
Uses:
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Mantle Cell Lymphoma (MCL)
Waldenström's Macroglobulinemia (WM)
Marginal Zone Lymphoma (MZL)
Chronic Graft versus Host Disease (cGVHD) in select cases
Storage Instructions:
Store at 20°C–25°C (68°F–77°F)
Protect from light and moisture
Keep in original container
Keep out of reach of children
How it Works (Mechanism of Action):
Ibrutinib selectively and irreversibly binds to Bruton's tyrosine kinase (BTK), an enzyme vital for B-cell receptor signaling.
Inhibition of BTK prevents survival and proliferation of malignant B-cells
Disrupts signaling needed for cancer cell migration and adhesion
Leads to cancer cell apoptosis (programmed cell death) and slows disease progression
Side Effects:
Common Side Effects:
Diarrhea
Fatigue
Nausea
Muscle pain
Bruising or bleeding
Upper respiratory tract infections
Serious Side Effects:
Atrial fibrillation or heart rhythm problems
Hypertension (high blood pressure)
Bleeding events (serious or fatal)
Infections (bacterial, viral, fungal)
Tumor lysis syndrome
Secondary cancers (rare)
Dosage (Typical Recommended Dose):
MCL: 560 mg once daily (usually 4 capsules of 140 mg)
CLL, SLL, WM: 420 mg once daily (3 capsules of 140 mg)
Doses may be modified based on tolerance and side effects
Take daily until disease progression or unacceptable toxicity
Method of Administration:
Take the capsule orally once daily with a full glass of water
Do not open, crush, or chew the capsules
Can be taken with or without food
Take at the same time every day for best results
Precautions:
Monitor for bleeding, heart rhythm changes, and infection
Not recommended during pregnancy or breastfeeding
Use effective contraception during and at least 1 month after treatment
Regular blood tests and ECGs may be required
Caution in patients with cardiac disorders or hypertension
